Fudan University Shanghai Cancer Center

Everest Medicines achieved 48% year-over-year revenue growth to RMB 446 million in H1 2025, driven by strong performance of NEFECON® and XERAVA®.

Researchers at Fudan University developed the Plasma Immuno Prediction Score (PIPscore) using six immune-related plasma proteins to predict immunotherapy response in triple-negative breast cancer with 85.8% accuracy.

Researchers developed and tested three Nectin-4-targeted PET radiotracers, with 68Ga-FZ-NR-1 showing the highest targeting efficacy in preclinical studies.

Everest Medicines has dosed the first patient with EVM16, its proprietary personalized mRNA cancer vaccine, in a first-in-human trial at Peking University Cancer Hospital in China.

• The phase 2 FDZL-001 trial investigated camrelizumab plus nab-paclitaxel, oxaliplatin, and fluorouracil (Nab-POF) for gastric/GEJ adenocarcinoma. • The combination therapy demonstrated a 75% R0 resection rate and an 88.5% overall response rate in treated patients. • After 3 years, the overall survival rate was 62.8%, and the progression-free survival rate was 56.9%, indicating durable responses. • The study suggests this regimen offers a new treatment option for initially unresectable, locally advanced, or metastatic gastric/GEJ adenocarcinoma.

A phase 2 trial reveals that tislelizumab combined with sitravatinib and nab-paclitaxel shows meaningful responses in patients with untreated locally advanced or recurrent triple-negative breast cancer (TNBC).

Camrelizumab plus chemotherapy significantly improved pathologic complete response (pCR) rates in early or locally advanced triple-negative breast cancer (TNBC).

The addition of cadonilimab to platinum-based chemotherapy, with or without bevacizumab, significantly improved progression-free survival (PFS) in patients with advanced cervical cancer.

Trastuzumab deruxtecan (T-DXd) maintains global health and quality of life (QOL) in patients with hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (MBC).